Residual viremia (RV) is present in most if not all patients who are responding well to highly activeantiretroviral therapy (HAART). It now appears that HAART reduces viremia to new steady state level thataverages around 1 copy of HIV-1 RNA/ml of plasma. This steady state appears to persist indefinitely with nofurther decay. Because the half life of virions in the plasma is short (minutes to hours), the continuedpresence of free virus in the plasma of patients on HAART indicates ongoing virus production. Thus it isclear that the sources of RV must be understood if HIV-1 eradication is to be achieved. In the previousfunding period, we have carried out the first study of intensification of a standard HAART regimen. Wefound that intensification fails to reduce RV, indicating that most of the RV results from release of virus fromstable reservoirs of cells infected prior to the initiation of therapy. These results indicate that the theoreticalpotential of HAART to control viremia has already been reached and that further progress towards HIVeradication will require new strategies that directly target stable reservoirs. Through the clonal analysis ofRV, we have also found that the RV there is at least one other source of RV in addition to the stablereservoir in resting CD4+ T cells. We now propose to continue studies of RV to obtain clones of replication-competent virus from the RV. This will provide direct evidence that the viruses constituting the RV are ofpotential clinical significance. In addition, in a new project prompted by the interest in our intensificationstudy, we will study patients who have stable low level viremia in the range of 75-400 copies/ml. Thesepatients currently represent a significant clinical dilemma. The presence of detectable viremia often triggersa change in regimen. However, it is possible that stable low level viremia reflects release of virus from stablereservoirs that are larger in some patients than in others. Thus we will carry out a detailed analysis of lowlevel viremia in these patients in order to provide a molecular explanation for persistent low level viremia andto obtain additional insight into stable viral reservoirs.
;Most pafients who are doing well on combination therapy for HIV infection have trace levels of free virus inthe blood called residual viremia. We have shown that this residual viremia is due to the release of virusfrom stable reservoirs of infected cells that persist despite the presence of antiretroviral drugs. Progresstowards HIV eradication will require the identification and elimination of these reservoirs.
|Spivak, Adam M; Rabi, S Alireza; McMahon, Moira A et al. (2011) Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses 27:759-61|
|Siliciano, Janet D; Siliciano, Robert F (2010) Biomarkers of HIV replication. Curr Opin HIV AIDS 5:491-7|
|McMahon, Moira A; Siliciano, Janet D; Kohli, Rahul M et al. (2010) Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. AIDS 24:319-23|
|Chase, Amanda J; Yang, Hung-Chih; Zhang, Hao et al. (2008) Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol 82:8307-15|
|Sedaghat, Ahmad R; German, Jennifer; Teslovich, Tanya M et al. (2008) Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 82:1870-83|
|Sedaghat, Ahmad R; Siliciano, Robert F; Wilke, Claus O (2008) Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 8:2|
|Sedaghat, Ahmad R; Dinoso, Jason B; Shen, Lin et al. (2008) Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A 105:4832-7|
|Shen, Lin; Peterson, Susan; Sedaghat, Ahmad R et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14:762-6|
|Domaoal, Robert A; McMahon, Moira; Thio, Chloe L et al. (2008) Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem 283:5452-9|
|Chase, Amanda J; Sedaghat, Ahmad R; German, Jennifer R et al. (2007) Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol 81:12748-57|
Showing the most recent 10 out of 11 publications